Indian Journal of Medical and Paediatric Oncology (Jan 2020)

Gastrointestinal stromal tumor – An overview

  • Anant Ramaswamy,
  • Vikram Chaudhari,
  • Prabhat Bhargava,
  • Manish Bhandare,
  • Rajiv Kumar,
  • Shailesh V Shrikhande,
  • Vikas Ostwal

DOI
https://doi.org/10.4103/ijmpo.ijmpo_45_20
Journal volume & issue
Vol. 41, no. 6
pp. 809 – 818

Abstract

Read online

Gastrointestinal stromal tumors (GISTs) are rare tumors but are most common mesenchymal tumors of the digestive tract. They are commonly seen in the stomach (60%) and small intestine (30%). GISTs are likely derived from the interstitial cells of Cajal or their stem cell precursors. They are best characterized by computerized tomography and have a specific staining pattern on immunohistochemistry, i.e., C-Kit and DOG-1. The treatment of GIST is based on the risk assessment for relapse, and patients with localized GIST require resection with or without adjuvant imatinib mesylate (IM). Advanced unresectable tumors are usually treated with IM, with a number of further options available for patients post progression on IM. There is an increasing emphasis on identifying C-Kit and platelet-derived growth factor receptor alpha mutations in all patients with GIST, as these are driver mutations with current and future therapeutic implications.

Keywords